Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127502 | 0.94 | LMNA (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2PKLR | |
| SCHEMBL1684873 | 0.87 | LMNA (0.40) | ALDH1A1LMNAMAPK1SMN1; SMN2PKLR | |
| SCHEMBL12003319 | 0.83 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPK1SMN1; SMN2PKLR | |
| SCHEMBL12215916 | 0.83 | LMNA (0.34) | ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL1684932 | 0.83 | PKM (0.33) | ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL19392741 | 0.83 | LMNA (0.34) | ALDH1A1LMNA | |
| SCHEMBL1684813 | 0.83 | HSD11B1 (0.32) | ALDH1A1LMNAMAPK1SMN1; SMN2PKLR | |
| SCHEMBL2125530 | 0.81 | LMNA (0.43) | ALDH1A1LMNAMAPK1SMN1; SMN2PKLR | |
| SCHEMBL1586762 | 0.80 | SMN1; SMN2 (0.41) | ALDH1A1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL1684946 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011050325-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | ALDH1A1 2535/4885LMNA 2078/4885MAPK1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.